1 week Ago By ABMN Staff
Ausdal Financial Partners Inc. boosted its position in shares of Merck & Co., Inc.
( NYSE:MRK – Free Report ) by 6.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 8,987 shares of the company’s stock after purchasing an additional 526 shares during the quarter.
Ausdal Financial Partners Inc.’s holdings in Merck & Co., Inc.
were worth $1,113,000 at the end of the most recent reporting period. Other institutional investors and hedge funds have also bought and sold shares of the company. Vermillion & White Wealth Management Group LLC bought a new position in shares of Merck & Co.
, Inc. during the fourth quarter valued at $27,000. Burkett Financial Services LLC purchased a new position in shares of Merck & Co.
, Inc. during the fourth quarter valued at approximately $28,000. Tidemark LLC bought a new position in Merck & Co.
, Inc. during the fourth quarter valued at approximately $31,000. Clear Investment Research LLC purchased a new stake in Merck & Co.
, Inc. in the fourth quarter worth approximately $39,000. Finally, Roble Belko & Company Inc boosted its holdings in Merck & Co.
, Inc. by 35.3% in the first quarter.
Roble Belko & Company Inc now owns 326 shares of the company’s stock worth $43,000 after purchasing an additional 85 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors.
Merck & Co., Inc. Price Performance NYSE:MRK opened at $117.
84 on Monday. The business’s 50-day simple moving average is $119.93 and its two-hundred day simple moving average is $125.
05. Merck & Co., Inc.
has a 52 week low of $99.14 and a 52 week high of $134.63.
The stock has a market cap of $298.47 billion, a PE ratio of 130.93, a P/E/G ratio of 1.
64 and a beta of 0.39. The company has a quick ratio of 1.
22, a current ratio of 1.47 and a debt-to-equity ratio of 0.80.
Merck & Co., Inc. Announces Dividend The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 7th.
Stockholders of record on Monday, September 16th will be given a dividend of $0.77 per share. This represents a $3.
08 annualized dividend and a dividend yield of 2.61%. The ex-dividend date is Monday, September 16th.
Merck & Co., Inc.’s payout ratio is currently 342.
22%. Analyst Upgrades and Downgrades A number of research analysts have weighed in on MRK shares. Morgan Stanley increased their target price on Merck & Co.
, Inc. from $132.00 to $134.
00 and gave the company an “equal weight” rating in a report on Thursday, July 11th. Barclays dropped their price objective on shares of Merck & Co., Inc.
from $145.00 to $142.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st.
Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 target price on shares of Merck & Co., Inc.
in a report on Thursday, August 29th. Evercore ISI upgraded shares of Merck & Co., Inc.
to a “strong-buy” rating in a research note on Tuesday, July 30th. Finally, Argus raised shares of Merck & Co., Inc.
to a “strong-buy” rating in a research report on Wednesday, June 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat.
com, the stock presently has a consensus rating of “Buy” and an average price target of $134.58. View Our Latest Report on Merck & Co.
, Inc. Merck & Co., Inc.
Profile ( Free Report ) Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
See Also Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co.
Inc. and related companies with MarketBeat.com's FREE daily email newsletter .
.
